Format

Send to

Choose Destination
Anticancer Res. 2018 Jun;38(6):3319-3322. doi: 10.21873/anticanres.12597.

mTOR Signalling Pathway-protein Expression in Post-transplant Cutaneous Squamous-cell Carcinomas Before and After Conversion to mTOR-inhibitors.

Author information

1
Department of Pathology, AHEPA Hospital, Aristotelian University of Thessaloniki, Thessaloniki, Greece.
2
Department of Dermatology, Ed. Herriot Hospital, Lyon, France.
3
Department of Dermatology, Ed. Herriot Hospital, Lyon, France jean.kanitakis@univ-lyon1.fr.
4
Department of Pathology, Ed. Herriot Hospital, Lyon, France.

Abstract

BACKGROUND/AIM:

Inhibitors of the mammalian target of rapamycin (mTORis) exert immunosuppressive and antitumor effects and are used in organ-transplant recipients (OTR) as immunosuppressants able to reduce skin tumor burden. This study investigated the effects of mTORis on the expression of mTOR pathway proteins in cutaneous squamous-cell carcinomas (SCC) developing in OTR, before and after switching to mTORis.

MATERIALS AND METHODS:

An immunohistochemical study was performed on 23 SCC sections excised from OTR with post-transplant SCC, before or after switch to mTORis, with antibodies against pAkt, pmTOR and PI3K.

RESULTS:

pmTOR expression was found in 8/12 SCC pre-switch, and in 8/11 SCC post-switch, to mTORis. All (but 2) SCC expressed PI3K, and all SCCs expressed pAkt.

CONCLUSION:

mTORis do not significantly change the immunohistochemical expression of molecules upstream of the mTOR inhibition (pmTOR, PI3K, pAkt), in cutaneous SCC.

KEYWORDS:

PI3K; immunohistochemistry; mTOR signaling; organ transplant recipients; pAkt; pmTOR; skin; squamous-cell carcinoma

PMID:
29848679
DOI:
10.21873/anticanres.12597
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for HighWire
Loading ...
Support Center